XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $804K invested in XTL Biopharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
287% more capital invested
Capital invested by funds: $208K → $804K (+$596K)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
6.78% more ownership
Funds ownership: 1.81% → 8.59% (+6.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$22.5K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.05K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$507 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$85K |
XTLB Hedge Fund Activity: Q4 2018 in Review
6 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2018, worth a combined $804K — up 287% from $208K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XTLB positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $22.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $85K sold.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2018, up from 4 in Q3 2018.
- Funds reported $804K of XTL Biopharmaceuticals stock for Q4 2018, up 287% quarter-over-quarter.
- 3 funds opened new XTL Biopharmaceuticals positions in Q4 2018 and 1 closed out, a net change of +2 holders.
- The largest XTL Biopharmaceuticals buyer in Q4 2018 was Morgan Stanley, an estimated $22.5K added.
- The largest XTL Biopharmaceuticals seller in Q4 2018 was Susquehanna International Group, an estimated $85K sold.
Based on aggregated 13F filings for Q4 2018.